UFF
PTCT icon

USA Financial Formulas’s PTC Therapeutics PTCT Stock Holding History

USA Financial Formulas’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-23,214
Closed -$465K – 324
2017
Q3 		$465K Buy
+23,214
New +$454K 0.11% 182

Other funds holding PTCT

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

USA Financial Formulas's PTCT Position: Q4 2017 in Review

USA Financial Formulas sold out of PTC Therapeutics (PTCT) in Q4 2017, closing a stake of 23,214 shares — an estimated $465K sold.

USA Financial Formulas first reported a position in PTCT in Q3 2017 and held it in 1 quarter. The position peaked at $465K in Q3 2017. 125 funds tracked by Wall St. Rank hold PTCT as of Q4 2017.

  • USA Financial Formulas reported no remaining PTC Therapeutics position as of Q4 2017 after selling out during the quarter.
  • USA Financial Formulas sold 23,214 PTC Therapeutics shares in Q4 2017, an estimated $465K.
  • USA Financial Formulas first reported a position in PTC Therapeutics in Q3 2017 and held it in 1 quarter.
  • USA Financial Formulas's PTC Therapeutics position peaked at $465K in Q3 2017.
  • 125 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2017.

Based on USA Financial Formulas's 13F filing for Q4 2017, filed 13 Feb 2018.